文献类型：期刊文献

中文题名：紫杉醇+卡铂联合与不联合贝伐珠单抗治疗晚期非小细胞肺癌临床效果的系统评价与Meta分析

英文题名：Clinical efficacy of paclitaxel and carboplatin with versus without bevacizumab in treatment of advanced non-small cell lung cancer:A systematic review and metaanalysis

作者：罗小桐[1,2];董信春[2];苟云久[2];金大成[2];张斯渊[1,2];黄大新[1,2]

第一作者：罗小桐

机构：[1]甘肃中医药大学第一临床医学院,兰州730000;[2]甘肃省人民医院胸外一科,兰州730000

第一机构：甘肃中医药大学临床医学院

年份：2023

卷号：30

期号：1

起止页码：126

中文期刊名：中国胸心血管外科临床杂志

外文期刊名：Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

收录：CSTPCD;;北大核心:【北大核心2020】；CSCD:【CSCD_E2023_2024】；

基金：甘肃省人民医院国家自然科学基金抚育项目(19SYPYB-28,19SYPYB-16);甘肃省卫生健康行业科研管理项目(GSWSKY2020-50);兰州市城关区创新创业项目(2020RCCX0010)。

语种：中文

中文关键词：贝伐珠单抗;紫杉醇;卡铂;非小细胞肺癌;系统评价/Meta分析

外文关键词：Bevacizumab;paclitaxel;carboplatin;non-small cell lung cancer;systematic review/meta-analysis

摘要：目的系统评价紫杉醇+卡铂联合与不联合贝伐珠单抗治疗非小细胞肺癌的临床疗效及不良反应。方法计算机检索PubMed、The Cochrane Library、EMbase、CNKI、Wanfang Data、VIP和CBM数据库,收集非小细胞肺癌患者使用紫杉醇+卡铂联合与不联合贝伐珠单抗临床疗效的随机对照试验,检索时限均为建库至2022年10月。采用RevMan 5.4软件进行Meta分析。结果纳入8项随机对照试验,共1724例患者。Meta分析结果显示:试验组(紫杉醇+卡铂联合贝伐珠单抗)治疗非小细胞肺癌,其疾病控制率、疾病缓解率、1年生存率、2年生存率均高于对照组(紫杉醇+卡铂)(P<0.05),但试验组治疗导致的白细胞减少症、出血、蛋白尿、高血压等不良反应发病率均高于对照组(P<0.05)。试验组与对照组疲乏、血小板减少、嗜中性白血球减少、低钠血症等方面差异无统计学意义(P>0.05)。试验组中位无进展生存时间、中位总体生存时间均长于对照组。结论紫杉醇+卡铂联合贝伐珠单抗治疗非小细胞肺癌在疾病控制、缓解,延长生存时间等方面更具优势,但不良反应更明显。
Objective To systematically evaluate the clinical efficacy and adverse reactions of paclitaxel and carboplatin with or without bevacizumab in the treatment of non-small cell lung cancer(NSCLC).Methods The databases including PubMed,The Cochrane Library,EMbase,CNKI,Wanfang Data,VIP and CBM were searched from inception to October 2022 to collect randomized controlled trials of the clinical efficacy of paclitaxel and carboplatin with or without bevacizumab for the treatment of NSCLC.RevMan 5.4 software was used for meta-analysis.Results Eight randomized controlled trials were enrolled,involving a total of 1724 patients.Meta-analysis showed that for the treatment of NSCLC,the disease control rate,overall response rate,1-year survival rate,and 2-year survival rate were higher in the trial group(paclitaxel and carboplatin combined with bevacizumab)than those in the control group(paclitaxel and carboplatin)(P<0.05);however,the incidences of the adverse reactions,such as leukopenia,hemorrhage,proteinuria and hypertension,etc,were higher in the trial group than those in the control group(P<0.05).There were no statistical differences between the trial group and the control group in the incidences of fatigue,thrombocytopenia,neutropenia or hyponatremia,etc(P>0.05).In addition,the median progression-free survival and overall survival were longer in the trial group than those in the control group.Conclusion For the treatment of NSCLC,paclitaxel and carboplatin combined with bevacizumab is superior in terms of disease control,overall response and prolonging patient survival,etc,but will be associated with more adverse reactions.